Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF (
Section 16. Form 4 or Form 5	
obligations may continue. See	

## CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FORMELA JEAN FRANCOIS					2. Issuer Name <b>and</b> Ticker or Trading Symbol Intellia Therapeutics, Inc. [ NTLA ]							Relationship leck all appli X Directo	cable)	g Pers	son(s) to Issu 10% Ow		
	ELLIA TH	ERAPEUTICS,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/17/2018								r (give title )		Other (s below)	pecify
40 ERIE STREET; SUITE 130				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	cambridge MA 02139				_								X Form f	Form filed by One Reporting Form filed by More than One Person			I
(City)	(5	State)	(Zip)														
		Tab	le I - Non	-Deriv	/ativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,			Code (Instr. 5)				Benefici	es ally Following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Transaci (Instr. 3	on(s)			(Instr. 4)	
		-							uired, Dis , options,				Owned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date Execution Date if any (Month/Day/Year)  (Month/Day/Year)		ate,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$25.98	05/17/2018			A		19,000		(1)	05/16/2028	Common Stock	19,000	\$0.00	19,000	0	D <sup>(2)</sup>	

## **Explanation of Responses:**

1. This option was granted on May 17, 2018 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

## Remarks:

/s/ Ommer Chohan, Attorney-

in-Fact

\*\* Signature of Reporting Person Date

05/21/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.